Osetron (Ondansetron Hydrochloride)

Ondansetron blocks serotonin 5‑HT3 receptors in the brain’s chemoreceptor trigger zone and along the gastrointestinal tract. This inhibition stops serotonin from activating the vomiting centre, thereby reducing the sensation of nausea and the act of vomiting.

The dose of Osetron is individualized by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and other medications. Healthcare professionals determine the appropriate strength, frequency and duration for each patient.

Safety data for ondansetron in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Osetron product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Osetron (ondansetron) belongs to the 5‑HT3 antagonist class, which is generally more effective for chemotherapy‑induced nausea than dopamine antagonists such as metoclopramide. It has a different side‑effect profile, with fewer extrapyramidal symptoms but a higher potential for QT prolongation.

Store Osetron at room temperature, below 25 °C, in its original container. Protect the product from moisture and direct sunlight to maintain stability. Do not refrigerate or freeze unless the packaging specifically indicates otherwise.

Osetron is taken orally. The tablet or oral formulation should be swallowed whole with water and can be taken with or without food, unless the prescribing information advises otherwise.

The most serious risks include QT interval prolongation that can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic agents. Patients should be monitored for any signs of these conditions.

Osetron should not be used by individuals with known hypersensitivity to ondansetron or any component of the formulation, and it is contraindicated in patients receiving apomorphine. Caution is also advised for patients with significant cardiac disease or electrolyte disturbances.